Cerulean Pharma

The company's primary product candidates were CRLX101 and CRLX301. CRLX101 was a nanoparticle-drug conjugate of camptothecin, a potent anti-tumor agent, designed to be released slowly within tumor cells. CRLX301 was similarly structured but carried docetaxel as its payload. The development strategy centered on advancing these candidates through clinical trials for various cancers, including in combination with other treatments like Avastin for renal cell carcinoma. The technology for CRLX101 was originally developed by Mark E. Davis at Caltech and licensed to Cerulean from Calando Pharmaceuticals in 2009.

Cerulean went public with an initial public offering in April 2014, trading under the NASDAQ symbol CERU. Despite raising significant venture capital and advancing its candidates to Phase 2 trials, the company faced major setbacks. In 2013 and again in 2016, its lead candidate, CRLX101, failed to meet primary endpoints in key clinical trials for lung and renal cancers, respectively. These failures led to significant workforce reductions and a strategic shift. In March 2017, Cerulean entered into a definitive stock purchase agreement with the privately-held Daré Bioscience. As part of this transition, Cerulean sold its clinical assets, CRLX101 and CRLX301, to BlueLink Pharmaceuticals, a subsidiary of NewLink Genetics, for $1.5 million. It also agreed to sell its Dynamic Tumor Targeting Platform to Novartis for $6 million. The transaction with Daré was a reverse merger, resulting in Daré Bioscience becoming a publicly traded company on NASDAQ under the symbol DARE, effective July 2017. The combined entity shifted its focus to women's reproductive health, marking the end of Cerulean Pharma's operations as an oncology-focused company.